Table 4.
Views of the hypertensive patients on statements about social value, risk and benefit of the pragmatic randomized controlled trial (pRCT) scenarios
| Statement | Scenario | Response, % | P value | ||
|---|---|---|---|---|---|
| Disagree | Neutral | Agree | |||
| It is valuable to study whether one treatment option is more effective than the other for treating high blood pressure | Drug pRCT a
Dose-timing pRCT b |
3.5 1.8 |
5.9 4.8 |
90.6 93.5 |
0.538 |
| Patients who participate in the randomized trial face greater risks than patients who receive usual care | Drug pRCT a
Dose-timing pRCT b |
31.8 40.5 |
27.6 25.6 |
40.6 33.9 |
0.233 |
| Patients who participate in the randomized trial are more likely to improve (lower) their high blood pressure than patients who receive usual care. | Drug pRCT a
Dose-timing pRCT b |
17.6 14.9 |
36.5 35.7 |
45.9 49.4 |
0.729 |
a n = 170
b n = 168